Mechanism of IL-8/miR-182 positive feedback regulatory axis in non-small cell lung cancer

doi:10.3969/j.issn.1673-8640.2022.04.009

Abstract

Abstract:

Objective To investigate the interaction between interleukin-8（IL-8） and microRNA-182（miR-182） in non-small cell lung cancer（NSCLC） and the mechanism of promoting the proliferation and migration of NSCLC. Methods A total of 40 patients with NSCLC（NSCLC group） were enrolled to collect preoperative serum samples and intraoperative cancer tissues and adjacent tissues. Another 40 healthy subjects（healthy control group） were enrolled as well. Serum IL-8 level and the expression level of miR-182 in cancer and adjacent tissues were determined. Cytological experiments were performed to analyze the effects of miR-182 and IL-8 on proliferation and migration of human NSCLC cell line A549,the regulatory effect of IL-8 on miR-182 and the signaling pathway of miR-182 affecting IL-8 expression. Results Serum IL-8 level in NSCLC group was higher than that in healthy control group（P<0.01）. The relative expression of miR-182 in cancer tissues of NSCLC patients was higher than that in adjacent tissues（P<0.01）. IL-8 promoted the proliferation and migration of A549 cells through miR-182. IL-8 up-regulated the expression of miR-182 through signal transducer and activator of transcription 3（STAT3）. MiR-182 up-regulated IL-8 expression by regulating nuclear factor-κB（NF-κB） signaling pathway. Conclusions Both IL-8 and miR-182 are highly expressed in NSCLC patients,and the positive feedback regulatory axis of IL-8/STAT3/miR-182/NF-κB/IL-8 promotes the occurrence and development of NSCLC.

Key words: Interleukin-8, MicroRNA-182, Proliferation, Migration, Non-small cell lung cancer

CLC Number:

R446.62

ZHAO Mingna, ZHANG Chenzi, HONG Qiushuang, LOU Jiatao. Mechanism of IL-8/miR-182 positive feedback regulatory axis in non-small cell lung cancer[J]. Laboratory Medicine, 2022, 37(4): 349-355.

Figures/Tables 8

References 13

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. DOI URL
[2]	CHERNI I, WEISS G J. MiRNAs in lung cancer:large roles for small players[J]. Future Oncol, 2011, 7(9):1045-1055. DOI URL
[3]	VISHNOI A, RANI S. MiRNA biogenesis and regulation of diseases:an overview[J]. Methods Mol Biol, 2017, 1509:1-10.
[4]	EDMONDS M D, BOYD K L, MOYO T, et al. MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer[J]. J Clin Invest, 2016, 126(1):349-364. DOI URL
[5]	SU Y L, WANG X, MANN M, et al. Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo[J]. Blood, 2020, 135(3):167-180. DOI URL
[6]	CALLAWAY C S, DELITTO A E, PATEL R, et al. IL-8 released from human pancreatic cancer and tumor-associated stromal cells signals through a CXCR2-ERK1/2 axis to induce muscle atrophy[J]. Cancers(Basel), 2019, 11(12):1863.
[7]	WEI Q, LEI R, HU G. Roles of miR-182 in sensory organ development and cancer[J]. Thorac Cancer, 2015, 6(1):2-9. DOI URL
[8]	NAGARSHETH N, WICHA M S, ZOU W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy[J]. Nat Rev Immunol, 2017, 17(9):559-572. DOI URL
[9]	ROSSI D, ZLOTNIK A. The biology of chemokines and their receptors[J]. Annu Rev Immunol, 2000, 18:217-242. DOI URL
[10]	HOU Y C, WANG C J, CHAO Y J, et al. Elevated serum interleukin-8 level correlates with cancer-related cachexia and sarcopenia:an indicator for pancreatic cancer outcomes[J]. J Clin Med, 2018, 7(12):502. DOI URL
[11]	SANMAMED M F, CARRANZA-RUA O, ALFARO C, et al. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins[J]. Clin Cancer Res, 2014, 20(22):5697-5707. DOI URL
[12]	SEGURA M F, HANNIFORD D, MENENDEZ S, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor[J]. Proc Natl Acad Sci U S A, 2009, 106(6):1814-1819. DOI URL
[13]	LEI R, TANG J, ZHUANG X, et al. Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis[J]. Oncogene, 2014, 33(10):1287-1296. DOI URL

[1]	ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811.
[2]	WANG Rong, XING Lianxiang, HUANG Keliang, LI Xin. MiR-374 promoting proliferation and invasion of breast cancer cells by targeting and down-regulating TRIM35 [J]. Laboratory Medicine, 2023, 38(9): 812-817.
[3]	YANG Yuqiang, QUAN Xiaoli, WANG Liuyu, XIAN Wenfeng, YANG Hong. Expression of RRBP1 in osteosarcoma tissues and its effect on cell biological characteristics [J]. Laboratory Medicine, 2023, 38(9): 842-848.
[4]	PENG Wei, LI Yungai, XU Jing, LIU Hua, YANG Cuixia, SHEN Yunyue. Serum inflammatory factors combined with PSA and f-PSA in the auxiliary diagnosis of prostate cancer [J]. Laboratory Medicine, 2023, 38(9): 849-854.
[5]	CHEN Ying, LI Wei, LIN Tao, YANG Li. Relationship between PFTK1 expression level and microvessel density and postoperative prognosis in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(7): 634-639.
[6]	PAN Xin, LÜ Ying, LI Yang, LI Rongguo. Effects of miR-24-3p targeting CHD5 on migration，invasion and radiosensitivity of thyroid cancer cells [J]. Laboratory Medicine, 2023, 38(7): 640-646.
[7]	ZHANG Ying, JING Lijuan, LI Li. Relationship between the expression of miR-138 in peripheral blood mononuclear cells of hepatitis B virus proliferation in carriers [J]. Laboratory Medicine, 2023, 38(6): 559-562.
[8]	LIANG Chaohui, ZHAO Fan, LIU Qianwen. Relationship between macrophage migration inhibitory factor and carotid vascular calcification in elderly patients with type 2 diabetes mellitus [J]. Laboratory Medicine, 2023, 38(5): 460-465.
[9]	YANG Zhongxin, LI Xiaoyu, CHEN Tao, CAO Wenjun. Roles of IL-8 and MMP-2 in the prognosis of non-small cell lung cancer patients after thoracoscopic segmentectomy [J]. Laboratory Medicine, 2023, 38(4): 342-346.
[10]	SONG Shiwei, LI Jingwu, LIN Tao, LIU Zeyu, WANG Zhiqiang, SUN Weidong. Relationship between GPNMB and non-small cell lung cancer immune infiltration and prognosis [J]. Laboratory Medicine, 2023, 38(4): 347-351.
[11]	GUO Shuang, LIU Hongli, LI Ya. Progression of migration and invasion-related miRNA and lncRNA in Epstein-Barr virus-associated gastric cancer [J]. Laboratory Medicine, 2023, 38(10): 987-996.
[12]	SHANG Zhenjun, WEI Wei, LIU Ruihan. Effect of inhibiting PTBP1 on the proliferation and invasiveness of choroidal melanoma cells [J]. Laboratory Medicine, 2023, 38(1): 51-55.
[13]	JI Ye, YUAN Xiaosun, ZHANG Lei, MA Huili, XUE Yongfei, LI Changsheng, ZHANG Jingwei, REN Zhonghai, ZHANG Tengfei. Expression of lncRNA HULC in papillary thyroid carcinoma tissues [J]. Laboratory Medicine, 2022, 37(7): 605-609.
[14]	XU Runhao, ZOU Chen, CAO Yun, CHEN Feng, LIU Yijing, ZHANG Shulin, ZHANG Jie. Roles of serum amino acid determinations in the diagnosis of early non-small-cell lung cancer [J]. Laboratory Medicine, 2022, 37(12): 1157-1163.
[15]	LI Mingwu, WANG Qinzhi, SUN Farui. Influence of MUC16 on the cell proliferation and invasion of osteosarcoma cells [J]. Laboratory Medicine, 2022, 37(10): 979-983.